Year Article Summary Read More


Pazopanib (Votrient) Gets FDA Approval for Advances Soft-Tissue Sarcoma

On April 27, 2012 the US Food and Drug Administration (FDA) approved pazopanib (Votrient), an oral multitargeted angiogenesis inhibitor, to treat patients with metastic soft-tissue sarcoma who have previously recieved chemotherapy. 

By Ian Ingram, April 27, 2012 CANCERNETWORK -- 


Systemic Therapy in Renal Cell Carcinoma: Advancing Paradigms

The 21st century has seen an explosion in the development of agents for renal-cell carcinoma (RCC), a malignancy previously considered refractory to systemic therapy beyond cytokine therapy. At this time, there are six US Food and Drug Administration (FDA)-approved agents available.


FDA Approves Targeted Pfizer Drug for Patients With Recurring Kidney Cancer 

The Food and Drug Administration approved the company's drug Inlyta as a secondary option for patients with renal cell carcinoma that hasn't responded to previous drug treatments. Click here to read the article online  

Washington Post: By Associated Press, Updated Friday January 27, 11:32 AM


Renal Cell Carcinoma Therapy in 2010: Many Options With Little Comparative Data

A bill signed into law in 2009 made comparative effectiveness studies a priority in medical research.  These studies are particularly useful for metastatic renal cell carcinoma, as there have been many overlapping results when using drugs to target the disease.  Comparative effectiveness studies take into consideration a number of factors, including prior drugs used by patients, stage of the illness, cost, etc.
Clinical Advances in Hematology & Oncology


Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Targeted therapies have drastically improved the ability to manage metastatic renal cell carcinoma.  The mTOR inhibitors help to regulate cell growth and survival, and as these drugs continue to be studied, their roles are being constantly revised and expanded.
Department of Medical Oncology and experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA


Breaking Through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporations of Biomarkers

There have been many recent developments in targeted therapies for metastatic renal cell carcinoma.  Oncologists were previously equipped with few treatment options, and now have many to work with.  Now, they must determine when to use the new therapies and on what types of patients.
American Association of Cancer Research


Targeted Therapies for Renal Cell Carcinoma: Understanding Their Impact on Survival

Six new drugs have been approved within the past five years for the treatment of metastatic renal cell carcinoma.  This has given hope to those suffering from the illness.  At the same time, clinicians are faced with the challenge of determining under which circumstances to use each drug.
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center (Online Article)


Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

Sunitinib, a drug that has been used in the treatment of several cancers, including kidney cancer, is used to stop tumors from making blood vessels that feed their growth.  The drug has been shown to improve the condition of metastatic renal cell carcinoma patients by inducing the death of tumor cells and stopping their growth.
Cancer Research --

Next >